Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06710132 · ClinicalTrials.gov registry record · Phase 1
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
A Phase 1 study of Pancreatic Cancer and Gastric Cancer, sponsored by EMD Serono Research & Development Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06710132 is a Phase 1 study of Pancreatic Cancer and Gastric Cancer that is actively recruiting participants, run by EMD Serono Research & Development Institute. The registered enrollment target is 250 participants, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06710132, a Phase 1 study of Pancreatic Cancer and Gastric Cancer, is actively recruiting participants, sponsored by EMD Serono Research & Development Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that may be conducted in parallel. * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC).
Conditions Studied
Interventions
- DRUG M9140
Study Locations (20)
Other
- Flinders Medical Centre - Bedford Park
- Nepean Cancer Care Centre - Kingswood
- Mater Misericordiae Ltd - PARENT - South Brisbane
- Macquarie University Hospital - PARENT - Sydney
- Ordensklinikum Linz Krankenhaus der Elisabethinen Linz - Pneumology - Linz
- LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie - Salzburg
- Medical University of Vienna - Department of Internal Medicine - Vienna
California
- University of California - Los Angeles - 300208353 - Santa Monica
- Providence Medical Foundation - Santa Rosa
Florida
- D&H Cancer Research Center - Margate
- Memorial Cancer Institute at Memorial Healthcare System - Pembroke Pines
Tennessee
- Baptist Cancer Center - Memphis
- Baptist Memorial Health Care -Memphis - Memphis
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- University of Texas M. D. Anderson Cancer Center - Partner - Houston
District of Columbia
- Georgetown University - Lombardi Comprehensive Cancer Center - 1134847 - Washington D.C.
South Carolina
- Prisma Health Cancer Institute, ITOR, CRU - Greenville
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-01-29 |
| Est. Completion | 2027-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06710132
The ClinicalTrials.gov registry entry for NCT06710132 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (36% lower). The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which M9140 is the first listed.
NCT06710132 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06710132 about?
NCT06710132 is a clinical study titled "Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)". The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics...
What is the current status of trial NCT06710132?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2025-01-29. Estimated completion is 2027-12-23.
What conditions does trial NCT06710132 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Gastric Cancer, Solid Tumors, Non-small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC).
What interventions are being tested in trial NCT06710132?
The interventions under investigation include: M9140 (DRUG).
Who is sponsoring clinical trial NCT06710132?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06710132 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, South Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.